Efficacy and safety of ribavirin therapy for chronic hepatitis E after kidney transplantation
Hepatitis E virus (HEV) infection has been recognized as an acute condition. However, recent reports have shown that immunocompromised patients, such as those receiving solid‐organ transplantation, can develop chronic hepatitis with HEV infection. We report two cases of chronic hepatitis E after kid...
Gespeichert in:
| Veröffentlicht in: | Hepatology research 2019-10, Vol.49 (10), p.1244-1248 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1248 |
|---|---|
| container_issue | 10 |
| container_start_page | 1244 |
| container_title | Hepatology research |
| container_volume | 49 |
| creator | Yoshida, Tomoaki Takamura, Masaaki Goto, Ryo Takeuchi, Suguru Tsuchiya, Atsunori Kamimura, Kenya Tasaki, Masayuki Nakagawa, Yuki Saito, Kazuhide Tomita, Yoshihiko Terai, Shuji |
| description | Hepatitis E virus (HEV) infection has been recognized as an acute condition. However, recent reports have shown that immunocompromised patients, such as those receiving solid‐organ transplantation, can develop chronic hepatitis with HEV infection. We report two cases of chronic hepatitis E after kidney transplantation (KT) who were successfully treated with ribavirin monotherapy.
Several years after KT, both patients had sustained elevations in the levels of liver enzymes for a period of more than 6 months. Both patients had HEV infection, genotype 3a. Histological studies showed infiltration of inflammatory cells without fibrosis. Treatment included ribavirin monotherapy at a dosage of 600 mg daily for 3 months. One month after therapy initiation, HEV‐RNA turned to negative, and remained negative at 24 weeks after ribavirin therapy without severe complications. Although the treatment of chronic hepatitis E is not fully established, ribavirin therapy can be a safe and effective treatment for chronic hepatitis E. |
| doi_str_mv | 10.1111/hepr.13363 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2231903213</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2313793385</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4473-d5212ad60814dc698b18ee753952d9dd94785b29fe39d00b5fbff5b0a11428fb3</originalsourceid><addsrcrecordid>eNp9kM9LwzAUx4Mobk4v_gES8CJCZ360TXuUUZ0wUETBi4S0SVjm1tYkVfrfm9npwYPv8h68D9_3-ABwitEUh7paqtZOMaUp3QNjnDESIRq_7IeZZmmU0jgdgSPnVghhhkh8CEYUI8YSxMbgtdDaVKLqoagldEIr38NGQ2tK8WGsqaFfKivaHurGwmppm9pUMFwU3njjYAGF9srCNyNr1UNvRe3atah92Df1MTjQYu3Uya5PwPNN8TSbR4v727vZ9SKq4pjRSCYEEyFTlOFYVmmelThTiiU0T4jMpcxjliUlybWiuUSoTHSpdVIigXFMMl3SCbgYclvbvHfKeb4xrlLr8IhqOscJoThHlARJE3D-B101na3DdzxAlOWUZkmgLgeqso1zVmneWrMRtucY8a10vpXOv6UH-GwX2ZUbJX_RH8sBwAPwadaq_yeKz4uHxyH0C8adjHo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2313793385</pqid></control><display><type>article</type><title>Efficacy and safety of ribavirin therapy for chronic hepatitis E after kidney transplantation</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Yoshida, Tomoaki ; Takamura, Masaaki ; Goto, Ryo ; Takeuchi, Suguru ; Tsuchiya, Atsunori ; Kamimura, Kenya ; Tasaki, Masayuki ; Nakagawa, Yuki ; Saito, Kazuhide ; Tomita, Yoshihiko ; Terai, Shuji</creator><creatorcontrib>Yoshida, Tomoaki ; Takamura, Masaaki ; Goto, Ryo ; Takeuchi, Suguru ; Tsuchiya, Atsunori ; Kamimura, Kenya ; Tasaki, Masayuki ; Nakagawa, Yuki ; Saito, Kazuhide ; Tomita, Yoshihiko ; Terai, Shuji</creatorcontrib><description>Hepatitis E virus (HEV) infection has been recognized as an acute condition. However, recent reports have shown that immunocompromised patients, such as those receiving solid‐organ transplantation, can develop chronic hepatitis with HEV infection. We report two cases of chronic hepatitis E after kidney transplantation (KT) who were successfully treated with ribavirin monotherapy.
Several years after KT, both patients had sustained elevations in the levels of liver enzymes for a period of more than 6 months. Both patients had HEV infection, genotype 3a. Histological studies showed infiltration of inflammatory cells without fibrosis. Treatment included ribavirin monotherapy at a dosage of 600 mg daily for 3 months. One month after therapy initiation, HEV‐RNA turned to negative, and remained negative at 24 weeks after ribavirin therapy without severe complications. Although the treatment of chronic hepatitis E is not fully established, ribavirin therapy can be a safe and effective treatment for chronic hepatitis E.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/hepr.13363</identifier><identifier>PMID: 31077507</identifier><language>eng</language><publisher>Netherlands: Wiley Subscription Services, Inc</publisher><subject>chronic hepatitis ; Chronic infection ; Fibrosis ; Genotypes ; Hepatitis ; hepatitis E virus ; Immunocompromised hosts ; immunocompromised patient ; Infections ; Inflammation ; Interferon ; Kidney transplantation ; Ribavirin ; Ribonucleic acid ; RNA</subject><ispartof>Hepatology research, 2019-10, Vol.49 (10), p.1244-1248</ispartof><rights>2019 The Japan Society of Hepatology</rights><rights>2019 The Japan Society of Hepatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4473-d5212ad60814dc698b18ee753952d9dd94785b29fe39d00b5fbff5b0a11428fb3</citedby><cites>FETCH-LOGICAL-c4473-d5212ad60814dc698b18ee753952d9dd94785b29fe39d00b5fbff5b0a11428fb3</cites><orcidid>0000-0001-6773-4613</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhepr.13363$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhepr.13363$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31077507$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshida, Tomoaki</creatorcontrib><creatorcontrib>Takamura, Masaaki</creatorcontrib><creatorcontrib>Goto, Ryo</creatorcontrib><creatorcontrib>Takeuchi, Suguru</creatorcontrib><creatorcontrib>Tsuchiya, Atsunori</creatorcontrib><creatorcontrib>Kamimura, Kenya</creatorcontrib><creatorcontrib>Tasaki, Masayuki</creatorcontrib><creatorcontrib>Nakagawa, Yuki</creatorcontrib><creatorcontrib>Saito, Kazuhide</creatorcontrib><creatorcontrib>Tomita, Yoshihiko</creatorcontrib><creatorcontrib>Terai, Shuji</creatorcontrib><title>Efficacy and safety of ribavirin therapy for chronic hepatitis E after kidney transplantation</title><title>Hepatology research</title><addtitle>Hepatol Res</addtitle><description>Hepatitis E virus (HEV) infection has been recognized as an acute condition. However, recent reports have shown that immunocompromised patients, such as those receiving solid‐organ transplantation, can develop chronic hepatitis with HEV infection. We report two cases of chronic hepatitis E after kidney transplantation (KT) who were successfully treated with ribavirin monotherapy.
Several years after KT, both patients had sustained elevations in the levels of liver enzymes for a period of more than 6 months. Both patients had HEV infection, genotype 3a. Histological studies showed infiltration of inflammatory cells without fibrosis. Treatment included ribavirin monotherapy at a dosage of 600 mg daily for 3 months. One month after therapy initiation, HEV‐RNA turned to negative, and remained negative at 24 weeks after ribavirin therapy without severe complications. Although the treatment of chronic hepatitis E is not fully established, ribavirin therapy can be a safe and effective treatment for chronic hepatitis E.</description><subject>chronic hepatitis</subject><subject>Chronic infection</subject><subject>Fibrosis</subject><subject>Genotypes</subject><subject>Hepatitis</subject><subject>hepatitis E virus</subject><subject>Immunocompromised hosts</subject><subject>immunocompromised patient</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Interferon</subject><subject>Kidney transplantation</subject><subject>Ribavirin</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kM9LwzAUx4Mobk4v_gES8CJCZ360TXuUUZ0wUETBi4S0SVjm1tYkVfrfm9npwYPv8h68D9_3-ABwitEUh7paqtZOMaUp3QNjnDESIRq_7IeZZmmU0jgdgSPnVghhhkh8CEYUI8YSxMbgtdDaVKLqoagldEIr38NGQ2tK8WGsqaFfKivaHurGwmppm9pUMFwU3njjYAGF9srCNyNr1UNvRe3atah92Df1MTjQYu3Uya5PwPNN8TSbR4v727vZ9SKq4pjRSCYEEyFTlOFYVmmelThTiiU0T4jMpcxjliUlybWiuUSoTHSpdVIigXFMMl3SCbgYclvbvHfKeb4xrlLr8IhqOscJoThHlARJE3D-B101na3DdzxAlOWUZkmgLgeqso1zVmneWrMRtucY8a10vpXOv6UH-GwX2ZUbJX_RH8sBwAPwadaq_yeKz4uHxyH0C8adjHo</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Yoshida, Tomoaki</creator><creator>Takamura, Masaaki</creator><creator>Goto, Ryo</creator><creator>Takeuchi, Suguru</creator><creator>Tsuchiya, Atsunori</creator><creator>Kamimura, Kenya</creator><creator>Tasaki, Masayuki</creator><creator>Nakagawa, Yuki</creator><creator>Saito, Kazuhide</creator><creator>Tomita, Yoshihiko</creator><creator>Terai, Shuji</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6773-4613</orcidid></search><sort><creationdate>201910</creationdate><title>Efficacy and safety of ribavirin therapy for chronic hepatitis E after kidney transplantation</title><author>Yoshida, Tomoaki ; Takamura, Masaaki ; Goto, Ryo ; Takeuchi, Suguru ; Tsuchiya, Atsunori ; Kamimura, Kenya ; Tasaki, Masayuki ; Nakagawa, Yuki ; Saito, Kazuhide ; Tomita, Yoshihiko ; Terai, Shuji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4473-d5212ad60814dc698b18ee753952d9dd94785b29fe39d00b5fbff5b0a11428fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>chronic hepatitis</topic><topic>Chronic infection</topic><topic>Fibrosis</topic><topic>Genotypes</topic><topic>Hepatitis</topic><topic>hepatitis E virus</topic><topic>Immunocompromised hosts</topic><topic>immunocompromised patient</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Interferon</topic><topic>Kidney transplantation</topic><topic>Ribavirin</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshida, Tomoaki</creatorcontrib><creatorcontrib>Takamura, Masaaki</creatorcontrib><creatorcontrib>Goto, Ryo</creatorcontrib><creatorcontrib>Takeuchi, Suguru</creatorcontrib><creatorcontrib>Tsuchiya, Atsunori</creatorcontrib><creatorcontrib>Kamimura, Kenya</creatorcontrib><creatorcontrib>Tasaki, Masayuki</creatorcontrib><creatorcontrib>Nakagawa, Yuki</creatorcontrib><creatorcontrib>Saito, Kazuhide</creatorcontrib><creatorcontrib>Tomita, Yoshihiko</creatorcontrib><creatorcontrib>Terai, Shuji</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshida, Tomoaki</au><au>Takamura, Masaaki</au><au>Goto, Ryo</au><au>Takeuchi, Suguru</au><au>Tsuchiya, Atsunori</au><au>Kamimura, Kenya</au><au>Tasaki, Masayuki</au><au>Nakagawa, Yuki</au><au>Saito, Kazuhide</au><au>Tomita, Yoshihiko</au><au>Terai, Shuji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of ribavirin therapy for chronic hepatitis E after kidney transplantation</atitle><jtitle>Hepatology research</jtitle><addtitle>Hepatol Res</addtitle><date>2019-10</date><risdate>2019</risdate><volume>49</volume><issue>10</issue><spage>1244</spage><epage>1248</epage><pages>1244-1248</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Hepatitis E virus (HEV) infection has been recognized as an acute condition. However, recent reports have shown that immunocompromised patients, such as those receiving solid‐organ transplantation, can develop chronic hepatitis with HEV infection. We report two cases of chronic hepatitis E after kidney transplantation (KT) who were successfully treated with ribavirin monotherapy.
Several years after KT, both patients had sustained elevations in the levels of liver enzymes for a period of more than 6 months. Both patients had HEV infection, genotype 3a. Histological studies showed infiltration of inflammatory cells without fibrosis. Treatment included ribavirin monotherapy at a dosage of 600 mg daily for 3 months. One month after therapy initiation, HEV‐RNA turned to negative, and remained negative at 24 weeks after ribavirin therapy without severe complications. Although the treatment of chronic hepatitis E is not fully established, ribavirin therapy can be a safe and effective treatment for chronic hepatitis E.</abstract><cop>Netherlands</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31077507</pmid><doi>10.1111/hepr.13363</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-6773-4613</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6346 |
| ispartof | Hepatology research, 2019-10, Vol.49 (10), p.1244-1248 |
| issn | 1386-6346 1872-034X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2231903213 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | chronic hepatitis Chronic infection Fibrosis Genotypes Hepatitis hepatitis E virus Immunocompromised hosts immunocompromised patient Infections Inflammation Interferon Kidney transplantation Ribavirin Ribonucleic acid RNA |
| title | Efficacy and safety of ribavirin therapy for chronic hepatitis E after kidney transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T05%3A19%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20ribavirin%20therapy%20for%20chronic%20hepatitis%20E%20after%20kidney%20transplantation&rft.jtitle=Hepatology%20research&rft.au=Yoshida,%20Tomoaki&rft.date=2019-10&rft.volume=49&rft.issue=10&rft.spage=1244&rft.epage=1248&rft.pages=1244-1248&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/hepr.13363&rft_dat=%3Cproquest_cross%3E2313793385%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2313793385&rft_id=info:pmid/31077507&rfr_iscdi=true |